It must be acknowledged that previous interventions such as radiotherapy, surgery, or hormonal treatment for breast or prostate cancer (aromatase inhibitors, exemestane, or fulvestrant) were not counted as previous lines of treatment as they are not administered nor dispensed at the Spanish hospital facilities and not registered in the treatment application. Here, CYP19A1 is linked to prostate carcinoma.